Biological descriptionH+ /K+-ATPase (proton pump) inhibitor (IC50 = 2.3 µM). S-enantiomer of omeprazole. Attenuates intestinal mucosal barrier damage and can promote healing of gastric lesions in rats. Also inhibits Cytochrome P450 2C19 (CYP2C9), CYP2C19 and CYP3A4 (Ki values are 81.5, 8.6 and 46.6 µM, respectively).
Chemical name6-Methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole sodium salt
Storage instructionsStore at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.
Solubility overviewSoluble in water to 100 mM, in ethanol to 100 mM and in DMSO to 100 mM
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
MDA-MB-231 cells were incubated at 37°C for 6h with vehicle control (0 µM) and 100 µM of esomeprazole sodium (ab120500). Increased expression of aryl hydrocarbon receptor (ab2770) correlates with an increase in esomeprazole sodium concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 20 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated with ab2770 at 2 µg/ml and ab8226 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-mouse antibody conjugated to HRP (ab97040) at 1/10000 dilution and visualised using ECL development solution.
References for Esomeprazole sodium (ab120500)
This product has been referenced in:
Fornai M et al. Effects of esomeprazole on healing of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers in the presence of a continued NSAID treatment: Characterization of molecular mechanisms. Pharmacol Res63:59-67 (2011).
Read more (PubMed: 20969958) »
Kodama K et al. E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion. J Pharmacol Exp Ther334:395-401 (2010).
Read more (PubMed: 20484556) »
Li XQ et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos32:821-7 (2004).
Read more (PubMed: 15258107) »